Shanghai De Novo Pharmatech Co. Ltd. has described antibody-immunostimulatory conjugates consisting of an antibody covalently bound to Toll-like receptor 8 (TLR8) agonists through a linker reported to be useful for the treatment of cancer.
Arbutus Biopharma Corp. has divulged programmed cell death protein 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, hepatitis B and hepatitis D infections.
Hanmi Holdings Co. Ltd. has identified serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) inhibitors described as potentially useful for the treatment of cancer.
Ariel Scientific Innovations Ltd. has synthesized microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer.
Multiple myeloma (MM) is still an uncurable disease. Chimeric antigen receptor (CAR) T cells directed to tumor necrosis factor receptor superfamily member 17, also known as BCMA, have transformed the field, with high response rate and durable remissions, but the access to this therapy is limited by multiple factors.
The FDA has cleared Oncoc4 Inc.’s IND application for ONC-841, a potential first-in-class Siglec-10-blocking antibody for the treatment of solid tumors.
Researchers from Kirilys Therapeutics Inc. presented findings from the preclinical evaluation of KRLS-017, a novel reversible cyclin-dependent kinase 7 (CDK7) inhibitor being developed for the treatment of advanced solid tumors.
Lung cancer is still among the deadliest cancers worldwide, with squamous cell carcinoma (SCC) of the lung accounting for about 30% of the cases. When the cancer metastasizes to the lymph nodes, the patient has a worse overall survival.
Researchers from Lund University published data from a study that investigated the role of cartilage oligomeric matrix protein (COMP), an extracellular matrix glycoprotein associated with the aggressiveness of several types of solid tumors, in ovarian cancer.
RSS
